Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte ( (MXCT) ) has provided an update.
MaxCyte, Inc. has announced a change in its major holdings, with BlackRock, Inc. increasing its voting rights to 10.27% as of June 10, 2025. This adjustment in holdings reflects BlackRock’s strategic positioning in MaxCyte, potentially impacting the company’s governance and decision-making processes.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, providing cell-engineering technology and services. The company focuses on enabling the development of cell-based therapies and has a significant presence in the life sciences sector.
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.